Consensus on the treatment of autoimmune bullous dermatoses: dermatitis herpetiformis and linear IgA bullous dermatosis - Brazilian Society of Dermatology
暂无分享,去创建一个
[1] A. Porro,et al. Adult linear IgA bullous dermatosis: report of three cases* , 2018, Anais brasileiros de dermatologia.
[2] K. Kaukinen,et al. Dermatitis Herpetiformis: A Common Extraintestinal Manifestation of Coeliac Disease , 2018, Nutrients.
[3] K. Kridin. Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations , 2018, Immunologic research.
[4] J. Zone,et al. Rituximab Treatment for Recalcitrant Dermatitis Herpetiformis , 2017, JAMA dermatology.
[5] K. Kaukinen,et al. Dermatitis herpetiformis: a cutaneous manifestation of coeliac disease , 2017, Annals of medicine.
[6] A. Porro,et al. Vancomycin-associated linear IgA disease mimicking toxic epidermal necrolysis* , 2016, Anais brasileiros de dermatologia.
[7] E. Antiga,et al. The diagnosis and treatment of dermatitis herpetiformis , 2015, Clinical, cosmetic and investigational dermatology.
[8] D. Sanders,et al. The gluten-free diet and its current application in coeliac disease and dermatitis herpetiformis , 2015, United European gastroenterology journal.
[9] A. Jakes,et al. Dermatitis herpetiformis , 2014, BMJ : British Medical Journal.
[10] G. Wozel,et al. Dapsone in dermatology and beyond , 2013, Archives of Dermatological Research.
[11] J. Roujeau,et al. Linear IgA bullous dermatosis: comparison between the drug‐induced and spontaneous forms , 2013, The British journal of dermatology.
[12] V. Aoki,et al. Linear IgA bullous dermatosis: report of an exuberant case* , 2013, Anais brasileiros de dermatologia.
[13] L. Borradori,et al. Acral Purpura as Leading Clinical Manifestation of Dermatitis Herpetiformis: Report of Two Adult Cases with a Review of the Literature , 2013, Dermatology.
[14] L. Kotze. Dermatitis herpetiformis, the celiac disease of the skin! , 2013, Arquivos de gastroenterologia.
[15] K. Kaukinen,et al. Reduced mortality in dermatitis herpetiformis: a population‐based study of 476 patients , 2012, The British journal of dermatology.
[16] D. Massi,et al. A further case of subacute prurigo‐like linear IgA bullous dermatosis: growing evidence of a new subset , 2012, International journal of dermatology.
[17] L. Sagi,et al. [Rituximab (Mabthera) for treatment of rare autoimmune bullous skin disorders]. , 2012, Harefuah.
[18] V. Venning. Linear IgA disease: clinical presentation, diagnosis, and pathogenesis. , 2012, Immunology and allergy clinics of North America.
[19] M. Solaymani-Dodaran,et al. The long‐term risk of malignancy following a diagnosis of coeliac disease or dermatitis herpetiformis: a cohort study , 2012, Alimentary pharmacology & therapeutics.
[20] S. Ng,et al. Management of linear IgA disease. , 2011, Dermatologic clinics.
[21] R. Hall,et al. Management of dermatitis herpetiformis. , 2011, Dermatologic clinics.
[22] J. A. Barclay,et al. Dapsone-Induced Methemoglobinemia: a Primer for Clinicians , 2011, The Annals of pharmacotherapy.
[23] R. Hall,et al. Pathophysiology of dermatitis herpetiformis: a model for cutaneous manifestations of gastrointestinal inflammation. , 2011, Dermatologic clinics.
[24] S. Kárpáti. An exception within the group of autoimmune blistering diseases: dermatitis herpetiformis, the gluten-sensitive dermopathy. , 2011, Dermatologic clinics.
[25] D. Bolotin,et al. Dermatitis herpetiformis: Part II. Diagnosis, management, and prognosis , 2011 .
[26] S. Steinberg,et al. Remission in dermatitis herpetiformis: a cohort study. , 2011, Archives of dermatology.
[27] J. E. Herrero-González. Guía clínica de diagnóstico y tratamiento de la dermatitis herpetiforme , 2010 .
[28] A. Karaa,et al. Linear IgA bullous dermatosis: the more frequent bullous dermatosis of children. , 2010, Dermatology online journal.
[29] Valeria Aoki,et al. Imunofluorescência direta e indireta , 2010 .
[30] E. Antiga,et al. Guidelines for the diagnosis and treatment of dermatitis herpetiformis , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.
[31] R. Hubbard,et al. No increase in risk of fracture, malignancy or mortality in dermatitis herpetiformis: a cohort study , 2008, Alimentary pharmacology & therapeutics.
[32] P. Hill,et al. Coeliac disease: a biopsy is not always necessary for diagnosis , 2008, Alimentary pharmacology & therapeutics.
[33] Antônio José Tebcherani,et al. Dermatose por IgA linear induzida pela gestação , 2008 .
[34] R. Rogers,et al. Clinical, pathologic, and immunopathologic features of dermatitis herpetiformis: review of the Mayo Clinic experience *, † , 2007, International journal of dermatology.
[35] C. Talhari,et al. Ocular linear IgA disease resulting in blindness. , 2006, Archives of dermatology.
[36] Michelle A. Pipitone,et al. Immunobullous diseases. , 2005, Journal of the American Academy of Dermatology.
[37] A. Cooper,et al. Sulfasalazine and dermatitis herpetiformis , 2005, The Australasian journal of dermatology.
[38] Arthur Rook,et al. Rook's Textbook of Dermatology , 2004 .
[39] M. Bardella,et al. Long‐term remission in patients with dermatitis herpetiformis on a normal diet , 2003, The British journal of dermatology.
[40] J. Murray,et al. Dermatitis herpetiformis , 2003, International journal of dermatology.
[41] L. Fry. Dermatitis herpetiformis: problems, progress and prospects. , 2002, European journal of dermatology : EJD.
[42] F. Wojnarowska,et al. Linear IgA disease: successful treatment with erythromycin , 2002, Clinical and experimental dermatology.
[43] C. Cockerell,et al. Characterization of a Subgroup of Patients With Dermatitis Herpetiformis With Nonclassical Histologic Features. , 2002, The American Journal of dermatopathology.
[44] D. Zillikens. BP180 as the common autoantigen in blistering diseases with different clinical phenotypes. , 2002, The Keio journal of medicine.
[45] L. Davis,et al. Localized linear IgA disease responding to colchicine , 2002, International journal of dermatology.
[46] D. Mutasim,et al. Immunofluorescence in dermatology. , 2001, Journal of the American Academy of Dermatology.
[47] J. Zone. Clinical Spectrum, Pathogenesis and Treatment of Linear IgA Bullous Dermatosis , 2001, The Journal of dermatology.
[48] M. Marinkovich,et al. Linear IgA bullous dermatosis. , 2001, Clinics in dermatology.
[49] L. Morrison,et al. Direct immunofluorescence microscopy in the diagnosis of autoimmune bullous dermatoses. , 2001, Clinics in dermatology.
[50] M. Stiller,et al. Dapsone and sulfones in dermatology: overview and update. , 2001, Journal of the American Academy of Dermatology.
[51] A. Ormerod,et al. Dermatitis herpetiformis effectively treated with heparin, tetracycline and nicotinamide , 2000, Clinical and experimental dermatology.
[52] J. Zone,et al. Linear IgA bullous dermatosis , 1999, International journal of dermatology.
[53] Bianchi,et al. The role of lymphocytes, granulocytes, mast cells and their related cytokines in lesional skin of linear IgA bullous dermatosis , 1999, The British journal of dermatology.
[54] J. Scott,et al. The blistering diseases. , 1998, The Medical clinics of North America.
[55] J. Garioch,et al. Protective effect of gluten‐free diet against development of lymphoma in dermatitis herpetiformis , 1996, The British journal of dermatology.
[56] E. Bröcker,et al. Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany. , 1995, Archives of dermatology.
[57] B. K. Park,et al. Cimetidine improves the therapeutic/toxic ratio of dapsone in patients on chronic dapsone therapy , 1995, The British journal of dermatology.
[58] J. Garioch,et al. 25 years' experience of a gluten‐free diet in the treatment of dermatitis herpetiformis , 1994, The British journal of dermatology.
[59] M. Black,et al. Chronic bullous disease of childhood and linear IgA disease of adults are IgA1‐mediated diseases , 1994, The British journal of dermatology.
[60] M. Coleman. Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance , 1993, The British journal of dermatology.
[61] T. Starink,et al. Efficacy of cyclosporine in two patients with dermatitis herpetiformis resistant to conventional therapy. , 1993, Journal of the American Academy of Dermatology.
[62] K. Neldner,et al. Successful treatment of dermatitis herpetiformis with tetracycline and nicotinamide in a patient unable to tolerate dapsone. , 1993, Journal of the American Academy of Dermatology.
[63] D. Fivenson,et al. Linear IgA bullous dermatosis: successful treatment with tetracycline and nicotinamide. , 1992, Journal of the American Academy of Dermatology.
[64] G. Guyatt,et al. The protective effect of vitamin E on the hemolysis associated with dapsone treatment in patients with dermatitis herpetiformis. , 1992, Archives of dermatology.
[65] B. G. Goldstein,et al. Sulfasalazine in dermatitis herpetiformis. , 1990, Journal of the American Academy of Dermatology.
[66] G. Kahn. Dapsone is safe during pregnancy. , 1985, Journal of the American Academy of Dermatology.
[67] K. Ljunghall,et al. Dermatitis herpetiformis: effect of gluten-restricted and gluten-free diet on dapsone requirement and on IgA and C3 deposits in uninvolved skin. , 1983, Acta dermato-venereologica.
[68] L. Fry,et al. Long term follow‐up of dermatitis herpetiformis with and without dietary gluten withdrawal , 1982, The British journal of dermatology.
[69] D. Silvers,et al. Treatment of dermatitis herpetiformis with colchicine. , 1980, Archives of dermatology.
[70] A. Almeida,et al. Dermatose bolhosa por IgA linear , 2019, Revista Médica de Minas Gerais.
[71] M. Marinkovich,et al. Linear immunoglobulin A bullous dermatosis. , 2012, Clinics in dermatology.
[72] S. Kárpáti,et al. Dermatitis herpetiformis. , 2012, Clinics in dermatology.
[73] D. Bolotin,et al. Dermatitis herpetiformis , 2011 .
[74] C. Bédane,et al. [Dermatitis herpetiformis. Guidelines for the diagnosis and treatment. Centres de référence des maladies bulleuses auto-immunes. Société Française de Dermatologie]. , 2011, Annales de dermatologie et de vénéréologie.
[75] S. Uzun,et al. Dermatitis herpetiformis in a patient receiving infliximab for ankylosing spondylitis. , 2008, European journal of dermatology : EJD.
[76] C. Talhari,et al. Ocular linear IgA disease resulting in blindness. Commentary , 2006 .
[77] H. Kerl,et al. UV light-induced linear IgA dermatosis. , 2004, Journal of the American Academy of Dermatology.
[78] Y. Tay,et al. Treatment of Linear IgA Bullous Dermatosis of Childhood with Colchicine , 1999, Pediatric dermatology.
[79] D. Miyamoto,et al. Longitudinal Evaluation of Manual Lymphatic Drainage For , 2022 .